{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:52:33Z","timestamp":1792785153803,"version":"4.5.0"},"reference-count":86,"publisher":"Georg Thieme Verlag KG","issue":"09","funder":[{"name":"Deutsche Forschungsgemeinschaft","award":["DFG CRC\/TR 412, Project-ID 535081457"],"award-info":[{"award-number":["DFG CRC\/TR 412, Project-ID 535081457"]}],"id":[{"id":"https:\/\/ror.org\/018mejw64","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z Gastroenterol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide, affecting around 30% of the population. It represents the hepatic manifestation of the metabolic syndrome and can progress to severe complications such as cirrhosis and hepatocellular carcinoma, with fibrosis as the key determinant of outcome. Current treatments, including the first liver-targeted pharmacotherapies, show limited efficacy in reversing fibrosis. The multidisciplinary consortium of the newly established transregional collaborative research center TRR 412 at the Charit\u00e9 Berlin and Dresden University of Technology aims to achieve a deeper mechanistic understanding of MASLD, promoting a holistic view that integrates pathogenic pathways of metabolic injury, inflammation, and fibrosis. MASLD is a complex and heterogeneous disease involving multiple liver cell types, and pathomechanisms are not (always) hierarchical, but intertwined across disease stages. In depth definition of the liver-specific molecular and cellular mechanisms driving MASLD progression will enable the development of innovative, mechanism-based therapies as well as improved patient stratification and personalized treatment approaches.<\/jats:p>","DOI":"10.1055\/a-2890-7253","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T22:39:39Z","timestamp":1784846379000},"page":"1261-1272","source":"Crossref","is-referenced-by-count":0,"title":["The new TRR 412 Metabolic Dysfunction-Associated Steatotic Liver Disease: From Pathophysiological Mechanisms to Translation into Tailored Therapeutic Concepts (Berlin \/ Dresden)"],"prefix":"10.1055","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6206-0226","authenticated-orcid":false,"given":"Frank","family":"Tacke","sequence":"additional","affiliation":[{"name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin, BE, Germany","place":["Berlin"],"department":["Hepatology and Gastroenterology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Detjen","sequence":"additional","affiliation":[{"name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin, BE, Germany","place":["Berlin"],"department":["Hepatology and Gastroenterology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Heisig","sequence":"additional","affiliation":[{"name":"Dresden University Hospital, SN, Germany","place":["Dresden"],"department":["Department of Medicine I"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Hampe","sequence":"additional","affiliation":[{"name":"Dresden University Hospital, SN, Germany","place":["Dresden"],"department":["Department of Medicine I"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity","year":"2024","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"ME Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.jhep.2025.12.026","article-title":"Is liver steatosis a disease or the emperor's new clothes?","volume":"84","author":"A Krag","year":"2026","journal-title":"J Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","article-title":"Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"V Raverdy","year":"2024","journal-title":"Nat Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1038\/s41591-024-03284-0","article-title":"Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"O Jamialahmadi","year":"2024","journal-title":"Nat Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jhep.2024.06.036","article-title":"Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease","volume":"81","author":"D Marti-Aguado","year":"2024","journal-title":"J Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/hepr.70067","article-title":"Young Adults Are at Highest Risk of Liver Fibrosis and Mortality Associated With Steatotic Liver Disease With Metabolic Dysfunction and Alcohol Consumption","volume":"56","author":"J Pustjens","year":"2026","journal-title":"Hepatol Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/LVT.0000000000000688","article-title":"Steatotic liver disease is the dominant indication for liver transplantation in both Europe and the United States: Trends and outcomes in the past 2 decades","volume":"32","author":"ZM Younossi","year":"2026","journal-title":"Liver Transpl"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-026-04801-3","article-title":"Global and regional prevalence, burden, and risk factors for MASLD in children and adolescents aged 5 to 24 years: a systematic review, meta-analysis, and modeling study","volume":"24","author":"Y Liu","year":"2026","journal-title":"BMC Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jhep.2026.02.016","article-title":"Update in clinical science: MASLD in children and adolescents","volume":"84","author":"S Lefere","year":"2026","journal-title":"J Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.cgh.2025.09.002","article-title":"Projected Global Clinical, Humanistic, and Economic Impact of Metabolic Dysfunction-Associated Steatohepatitis (MASH): The Cost of Inaction Based on Data From Nine Countries","volume":"24","author":"ZM Younossi","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"SA Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis","volume":"392","author":"AJ Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jhep.2025.02.033","article-title":"Integrative metabolism in MASLD and MASH: Pathophysiology and emerging mechanisms","volume":"83","author":"GR Steinberg","year":"2025","journal-title":"J Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/dom.70545","article-title":"Providing holistic care for patients with metabolic dysfunction-associated steatotic liver disease\/metabolic dysfunction-associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions","volume":"28","author":"L Chen","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","article-title":"An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH","volume":"79","author":"F Tacke","year":"2023","journal-title":"J Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","article-title":"Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis","volume":"158","author":"RF Schwabe","year":"2020","journal-title":"Gastroenterology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1172\/JCI186420","article-title":"MASH: the nexus of metabolism, inflammation, and fibrosis","volume":"135","author":"GR Steinberg","year":"2025","journal-title":"J Clin Invest"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41575-020-00365-6","article-title":"Maladaptive regeneration \u2013 the reawakening of developmental pathways in NASH and fibrosis","volume":"18","author":"C Zhu","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat0344","article-title":"Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis","volume":"10","author":"C Zhu","year":"2018","journal-title":"Sci Transl Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.cell.2015.01.012","article-title":"Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes","volume":"160","author":"RJ Perry","year":"2015","journal-title":"Cell"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","article-title":"Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases","volume":"27","author":"VT Samuel","year":"2018","journal-title":"Cell Metab"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1136\/gutjnl-2023-331741","article-title":"Nuclear receptors: pathophysiological mechanisms and drug targets in liver disease","volume":"73","author":"V Dubois","year":"2024","journal-title":"Gut"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","article-title":"Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors","volume":"18","author":"S Francque","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.05.052","article-title":"Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of Art Update","author":"S Sookoian","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/s41586-025-09884-1","article-title":"Human assembloids recapitulate periportal liver tissue in vitro","volume":"650","author":"L Yuan","year":"2026","journal-title":"Nature"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1136\/gutjnl-2024-334425","article-title":"Reactive cholangiocyte-derived ORM2 drives a pathogenic modulation of the injured biliary niche through macrophage reprogramming","volume":"74","author":"H Liu","year":"2025","journal-title":"Gut"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jhep.2025.11.018","article-title":"Modeling immune lineage co-development in human pluripotent stem cell-derived liver organoids","volume":"84","author":"M Rezvani","year":"2026","journal-title":"J Hepatol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-pathol-020117-043617","article-title":"Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease","volume":"13","author":"JP Arab","year":"2018","journal-title":"Annu Rev Pathol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020652","article-title":"The Potential Role of Cellular Senescence in Non-Alcoholic Fatty Liver Disease","volume":"23","author":"C Engelmann","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","article-title":"Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease \u2013 novel insights into cellular communication circuits","volume":"77","author":"M Peiseler","year":"2022","journal-title":"J Hepatol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41586-020-2977-2","article-title":"Commensal-driven immune zonation of the liver promotes host defence","volume":"589","author":"A Gola","year":"2021","journal-title":"Nature"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/s41586-024-07372-6","article-title":"Periportal macrophages protect against commensal-driven liver inflammation","volume":"629","author":"Y Miyamoto","year":"2024","journal-title":"Nature"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.jcmgh.2023.03.002","article-title":"The Multifaceted Roles of Macrophages in NAFLD Pathogenesis","volume":"15","author":"J Vonderlin","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/hep.29544","article-title":"Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis","volume":"67","author":"O Krenkel","year":"2018","journal-title":"Hepatology"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nri3623","article-title":"Liver fibrosis and repair: immune regulation of wound healing in a solid organ","volume":"14","author":"A Pellicoro","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41575-020-0304-x","article-title":"Single-cell technologies in hepatology: new insights into liver biology and disease pathogenesis","volume":"17","author":"P Ramachandran","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/j.immuni.2021.08.006","article-title":"A subset of Kupffer cells regulates metabolism through the expression of CD36","volume":"54","author":"C Bleriot","year":"2021","journal-title":"Immunity"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.immuni.2020.08.004","article-title":"Osteopontin Expression Identifies a Subset of Recruited Macrophages Distinct from Kupffer Cells in the Fatty Liver","volume":"53","author":"A Remmerie","year":"2020","journal-title":"Immunity"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.immuni.2020.04.001","article-title":"Niche-Specific Reprogramming of Epigenetic Landscapes Drives Myeloid Cell Diversity in Nonalcoholic Steatohepatitis","volume":"52","author":"JS Seidman","year":"2020","journal-title":"Immunity"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.immuni.2020.06.003","article-title":"Impaired Kupffer Cell Self-Renewal Alters the Liver Response to Lipid Overload during Non-alcoholic Steatohepatitis","volume":"53","author":"S Tran","year":"2020","journal-title":"Immunity"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108626","article-title":"Dynamic Shifts in the Composition of Resident and Recruited Macrophages Influence Tissue Remodeling in NASH","volume":"34","author":"S Daemen","year":"2021","journal-title":"Cell Rep"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1136\/gutjnl-2019-318382","article-title":"Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis","volume":"69","author":"O Krenkel","year":"2020","journal-title":"Gut"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.cell.2019.05.054","article-title":"Lipid-Associated Macrophages Control Metabolic Homeostasis in a Trem2-Dependent Manner","volume":"178","author":"DA Jaitin","year":"2019","journal-title":"Cell"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101421","article-title":"Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease","volume":"7","author":"RF Schwabe","year":"2025","journal-title":"JHEP Rep"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/s41590-025-02255-y","article-title":"Single-cell atlas of human liver and blood immune cells across fatty liver disease stages reveals distinct signatures linked to liver dysfunction and fibrogenesis","volume":"26","author":"OP Martin","year":"2025","journal-title":"Nat Immunol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.jhep.2022.06.004","article-title":"Soluble TREM2 levels reflect the recruitment and expansion of TREM2(+) macrophages that localize to fibrotic areas and limit NASH","volume":"77","author":"T Hendrikx","year":"2022","journal-title":"J Hepatol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2405746121","article-title":"Lipid-associated macrophages' promotion of fibrosis resolution during MASH regression requires TREM2","volume":"121","author":"S Ganguly","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1016\/j.immuni.2024.08.016","article-title":"Notch signaling regulates macrophage-mediated inflammation in metabolic dysfunction-associated steatotic liver disease","volume":"57","author":"W Guo","year":"2024","journal-title":"Immunity"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1126\/science.abq5202","article-title":"Kupffer cell-like syncytia replenish resident macrophage function in the fibrotic liver","volume":"381","author":"M Peiseler","year":"2023","journal-title":"Science"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41586-019-1631-3","article-title":"Resolving the fibrotic niche of human liver cirrhosis at single-cell level","volume":"575","author":"P Ramachandran","year":"2019","journal-title":"Nature"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.cell.2021.12.018","article-title":"Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches","volume":"185","author":"M Guilliams","year":"2022","journal-title":"Cell"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41591-019-0379-5","article-title":"Platelet GPIbalpha is a mediator and potential interventional target for NASH and subsequent liver cancer","volume":"25","author":"M Malehmir","year":"2019","journal-title":"Nat Med"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nm.4294","article-title":"An emerging role for neutrophil extracellular traps in noninfectious disease","volume":"23","author":"SK Jorch","year":"2017","journal-title":"Nat Med"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.jhep.2013.12.005","article-title":"A TLR2\/S100A9\/CXCL-2 signaling network is necessary for neutrophil recruitment in acute and chronic liver injury in the mouse","volume":"60","author":"A Moles","year":"2014","journal-title":"J Hepatol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/s41591-021-01344-3","article-title":"XCR1(+) type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis","volume":"27","author":"A Deczkowska","year":"2021","journal-title":"Nat Med"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ccell.2014.09.003","article-title":"Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes","volume":"26","author":"MJ Wolf","year":"2014","journal-title":"Cancer Cell"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41586-021-03233-8","article-title":"Auto-aggressive CXCR6(+) CD8 T cells cause liver immune pathology in NASH","volume":"592","author":"M Dudek","year":"2021","journal-title":"Nature"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jhep.2023.04.037","article-title":"Intestinal B cells license metabolic T-cell activation in NASH microbiota\/antigen-independently and contribute to fibrosis by IgA-FcR signalling","volume":"79","author":"E Kotsiliti","year":"2023","journal-title":"J Hepatol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41575-019-0210-2","article-title":"Adaptive immunity: an emerging player in the progression of NAFLD","volume":"17","author":"S Sutti","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1002\/hep.31889","article-title":"The Emerging Role of B Cells in the Pathogenesis of NAFLD","volume":"74","author":"F Barrow","year":"2021","journal-title":"Hepatology"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.cell.2018.07.017","article-title":"Innate Lymphoid Cells: 10 Years On","volume":"174","author":"E Vivier","year":"2018","journal-title":"Cell"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1136\/gutjnl-2011-301400","article-title":"NKp46-mediated killing of human and mouse hepatic stellate cells attenuates liver fibrosis","volume":"61","author":"C Gur","year":"2012","journal-title":"Gut"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.640869","article-title":"Revisiting the Role of Natural Killer Cells in Non-Alcoholic Fatty Liver Disease","volume":"12","author":"ML Martinez-Chantar","year":"2021","journal-title":"Front Immunol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.immuni.2016.06.016","article-title":"Adipose-Resident Group 1 Innate Lymphoid Cells Promote Obesity-Associated Insulin Resistance","volume":"45","author":"TE O'Sullivan","year":"2016","journal-title":"Immunity"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/nature14115","article-title":"Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity","volume":"519","author":"JR Brestoff","year":"2015","journal-title":"Nature"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.jcmgh.2023.02.010","article-title":"Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease","volume":"15","author":"L Wiering","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1038\/ncomms3823","article-title":"Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology","volume":"4","author":"I Mederacke","year":"2013","journal-title":"Nat Commun"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41586-022-05289-6","article-title":"Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis","volume":"610","author":"A Filliol","year":"2022","journal-title":"Nature"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.adf6696","article-title":"Hepatic stellate cells maintain liver homeostasis through paracrine neurotrophin-3 signaling that induces hepatocyte proliferation","volume":"16","author":"VQ Trinh","year":"2023","journal-title":"Sci Signal"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100524","article-title":"Understanding the cellular interactome of non-alcoholic fatty liver disease","volume":"4","author":"SJ Wallace","year":"2022","journal-title":"JHEP Rep"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jcmgh.2024.01.002","article-title":"\u201cThe Good, the Bad, and the Ugly\u201d \u2013 About Diverse Phenotypes of Hepatic Stellate Cells in the Liver","volume":"17","author":"A Bogomolova","year":"2024","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","article-title":"Hepatic inflammatory responses in liver fibrosis","volume":"20","author":"L Hammerich","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/s41586-025-08677-w","article-title":"Hepatic stellate cells control liver zonation, size and functions via R-spondin 3","volume":"640","author":"A Sugimoto","year":"2025","journal-title":"Nature"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"T Kisseleva","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"T Tsuchida","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.jhep.2021.02.012","article-title":"Targeting cell-intrinsic metabolism for antifibrotic therapy","volume":"74","author":"H Gilgenkrantz","year":"2021","journal-title":"J Hepatol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","article-title":"Senolytic CAR T cells reverse senescence-associated pathologies","volume":"583","author":"C Amor","year":"2020","journal-title":"Nature"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jhep.2024.01.034","article-title":"Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models","volume":"80","author":"H Dai","year":"2024","journal-title":"J Hepatol"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jhep.2024.03.014","article-title":"Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatohepatitis","volume":"81","author":"CN Yashaswini","year":"2024","journal-title":"J Hepatol"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.jhep.2024.10.044","article-title":"Multi-modal analysis of human hepatic stellate cells identifies novel therapeutic targets for metabolic dysfunction-associated steatotic liver disease","volume":"82","author":"HY Kim","year":"2025","journal-title":"J Hepatol"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s42255-024-01043-6","article-title":"An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"6","author":"M Vacca","year":"2024","journal-title":"Nat Metab"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41590-024-01842-9","article-title":"Leveraging dirty mice that have microbial exposure to improve preclinical models of human immune status and disease","volume":"25","author":"Q Liu","year":"2024","journal-title":"Nat Immunol"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41586-025-09183-9","article-title":"Mouse liver assembloids model periportal architecture and biliary fibrosis","volume":"644","author":"AM Dowbaj","year":"2025","journal-title":"Nature"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202403516","article-title":"Dissecting Acute Drug-Induced Hepatotoxicity and Therapeutic Responses of Steatotic Liver Disease Using Primary Mouse Liver and Blood Cells in a Liver-On-A-Chip Model","volume":"11","author":"H Liu","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41575-024-00919-y","article-title":"Artificial intelligence in liver cancer \u2013 new tools for research and patient management","volume":"21","author":"J Calderaro","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["Zeitschrift f\u00fcr Gastroenterologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2890-7253.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:31:16Z","timestamp":1790202676000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2890-7253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":86,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2026,9,23]]},"published-print":{"date-parts":[[2026,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2890-7253","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0044-2771","1439-7803"],"issn-type":[{"value":"0044-2771","type":"print"},{"value":"1439-7803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]}}}